search
Back to results

Daratumumab and Belatacept for Desensitization (ATTAIN)

Primary Purpose

Highly Sensitized Prospective Kidney Transplant Recipients

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
daratumumab
belatacept
Bone marrow aspiration
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Highly Sensitized Prospective Kidney Transplant Recipients focused on measuring calculated panel reactive antibodies (cPRA), desensitization therapy, human leukocyte antigen (HLA) desensitization

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Individuals who meet all of the following criteria are eligible for enrollment as study subjects-

  1. Subject must be able to understand and provide informed consent
  2. End stage renal disease (ESRD) on hemodialysis
  3. United Network for Organ Sharing (UNOS) listed listed with current calculated panel reactive antibodies (cPRA) ≥99.9% or >98% (with >5 years of waiting time) awaiting deceased donor transplant

    --Note: Those with cPRA >98% with human leukocyte antigen (HLA)-incompatible approved living donor who have not received a transplant after 1 year in a paired kidney exchange program are also eligible

  4. Evidence of established immunity to Epstein-Barr Virus (EBV) as demonstrated by serologic testing
  5. Negative result of most recent tuberculosis (TB) testing or appropriately completed latent TB infection (LTBI) therapy.

    • Testing should be conducted using either a PPD or interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB)
    • Results from tests performed within 12 months prior to study entry are acceptable in the absence of any intervening exposure to TB
    • Subjects with a positive test for LTBI must complete appropriate therapy for LTBI ---LTBI treatment regimens should be among those endorsed by the Centers for

    Disease Control and Prevention (CDC), Division of TB Elimination, url:

    https://www.cdc.gov/tb/topic/treatment/ltbi.htm

  6. Negative Food and Drug Administration (FDA)-approved test for human immunodeficiency virus (HIV) diagnosis (at screening or as documented in medical record, up to 12 months prior to screening)
  7. Negative Hepatitis C antibody test at screening or as documented in medical record, up to 12 months prior to screening

    --If there is a history of treated hepatitis C or there is a suspected false positive hepatitis C virus (HCV) antibody test, then documentation of two consecutive negative HCV quantitative ribonucleic acid (RNA) Polymerase chain reaction (PCR) tests separated by at least 6 months is required

  8. Negative result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase (RT-PCR)
  9. Female subjects of reproductive potential must have a negative pregnancy test upon study entry
  10. All subjects of reproductive potential must agree to use of contraception for the duration of the study
  11. Subjects must have current vaccinations or documented immunity to varicella, measles, hepatitis B, pneumococcus, influenza, and zoster (if ≥50 years old)

    • If subjects require administration of vaccines to meet eligibility requirements, they must wait at least 2 weeks between vaccination and the baseline (Visit 0) visit

Exclusion Criteria:

Individuals who meet any of these criteria are not eligible for enrollment as study subjects-

  1. Inability or unwillingness of a subject to give written informed consent or comply with study protocol
  2. Known active current or history of invasive fungal infection or non-tuberculous mycobacterial infection
  3. Hepatitis B surface antigen or core antibody positive
  4. Serious uncontrolled concomitant major organ disease excluding kidney failure
  5. Previous non-kidney solid organ or bone marrow transplant
  6. Any infection requiring hospitalization and intravenous (IV) antibiotics within 4 weeks of screening or by mouth (PO) antibiotics within 2 weeks
  7. Primary or secondary immunodeficiency
  8. History of active tuberculosis (TB), even if treated
  9. History of positive result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase (RT-PCR)
  10. Malignancy within the last 5 years except treated basal and squamous cell cancer of the skin or treated in situ cervical cancer
  11. History of plasma cell dyscrasia
  12. Alcohol, drug, or chemical abuse within 1 year
  13. Difficult peripheral venous access
  14. Need for uninterrupted anticoagulation
  15. Neutropenia (absolute neutrophil count <1000/uL) or thrombocytopenia (platelet count <100,000/uL) within 4 weeks prior to study enrollment
  16. Women who are currently pregnant or nursing
  17. Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational drug, whichever is longer) of screening
  18. Current treatment with other biological drug
  19. Immunization with live vaccine within 2 weeks of study baseline (Visit 0) visit
  20. Past or current medical problems or findings from physical examination or laboratory testing not listed above, which, in the opinion of the investigator, may:

    • pose additional risks from participation in the study,
    • interfere with the subject's ability to comply with study requirements, or
    • impact the quality or interpretation of the data obtained from the study

Sites / Locations

  • University of California at San Francisco Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cohort 1 (N=5 Subjects)

Cohort 2 (N=10 Subjects)

Arm Description

Multiple intravenous infusions of daratumumab and belatacept over 10 weeks: Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit. Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%.

The enrollment of ten additional subjects is dependent on the results in Cohort 1. Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:° Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit. Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%. May be modified based on the safety and efficacy analysis of Cohort 1.

Outcomes

Primary Outcome Measures

Proportion of subjects who have not met a subject stopping rule and remain free of all of the safety events listed in the outcome description, through 26 weeks after starting treatment or until receiving a transplant, whichever occurs earlier
Proportion of subjects who have not met a subject stopping rule, and remain free of all of the following through 26 weeks after starting treatment or until receiving a transplant, whichever occurs earlier: Grade 3 or higher infusion reaction Grade 3 or higher infections Any malignancy The study site will grade the severity of adverse events experienced by the study subjects according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (Published November 27, 2017).
Proportion of subjects who meet any one of the pre-specified events detailed in the outcome description: from Baseline up to Week 26
Proportion of subjects who meet any one of the following compared to Baseline (Visit 0): Elimination of one human leukocyte antigen (HLA) antibody at Visit 12 (16 weeks ±7 days after starting treatment); 50% or greater reduction in the mean fluorescence intensity (MFI) of at least three HLA antibodies at Visit 12 (16 weeks ±7 days after starting treatment); and/or Kidney transplant with a previously incompatible donor within 26 weeks after starting treatment without graft loss due to acute antibody mediated rejection occurring within the first four weeks post-transplant and caused by an anamnestic response.

Secondary Outcome Measures

Proportion of subjects transplanted with a previously incompatible donor within 52 weeks after starting treatment
Subjects may receive a kidney transplant while in the study, either from a living or deceased donor to whom they were previously compatible, or from a previously incompatible donor in case there is a significant reduction in HLA antibody.
Proportion of subjects with biopsy-proven acute or chronic antibody mediated rejection (AMR) within 52 weeks post-transplant in subjects who undergo a kidney transplant
Antibody mediated rejection (AMR) is an important cause of graft loss after organ transplantation and is caused by anti-donor-specific antibodies, especially anti- human leukocyte antigen (HLA) antibodies.
Number of biopsy-proven acute or chronic AMR events within 52 weeks post-transplant in subjects who undergo a kidney transplant
Antibody mediated rejection (AMR) is an important cause of graft loss after organ transplantation and is caused by anti-donor-specific antibodies, especially anti- human leukocyte antigen (HLA) antibodies.
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 16 weeks after starting treatment
A measure of infection-related morbidity.
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 26 weeks after starting treatment
A measure of infection-related morbidity.
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 52 weeks after starting treatment
A measure of infection-related morbidity.
Incidence of cytomegalovirus (CMV) disease within 16 weeks after starting treatment
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Incidence of cytomegalovirus (CMV) disease within 26 weeks after starting treatment
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Incidence of cytomegalovirus (CMV) disease within 52 weeks after starting treatment
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Incidence of cytomegalovirus (CMV) infection within 52 weeks after starting treatment
CMV infection confirmed by the presence of detectable CMV in blood by polymerase chain reaction [PCR] diagnostic testing, regardless of whether signs or symptoms are present.
Incidence of post-transplant lymphoproliferative disorder (PTLD)
As per diagnosis by local pathologist and treating physician.

Full Information

First Posted
March 30, 2021
Last Updated
February 22, 2023
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Immune Tolerance Network (ITN), Bristol-Myers Squibb, PPD, Rho Federal Systems Division, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04827979
Brief Title
Daratumumab and Belatacept for Desensitization
Acronym
ATTAIN
Official Title
A Mechanistically Driven Therapy to Desensitize >98.0% cPRA Patients: Depletion of Plasma Cells With Anti-CD38 and Prevention of B Cell Activation With Costimulation Blockade (ITN090ST)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2021 (Actual)
Primary Completion Date
April 2025 (Anticipated)
Study Completion Date
July 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Immune Tolerance Network (ITN), Bristol-Myers Squibb, PPD, Rho Federal Systems Division, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors. Being "highly sensitized" means that they will likely have to wait a long time (more than 5 years) before an acceptable donor is found for them or, they never receive a compatible donor, and die on waitlist. The purpose of this study is to find out whether two drugs, daratumumab (Darzalex®), and belatacept (Nulojix®), can make these kidney transplant candidates less sensitized, and make it easier and quicker to find a kidney donor for them.
Detailed Description
This study will enroll 15 eligible adult participants with end stage renal failure on dialysis who are on the waiting list for a deceased donor transplant with calculated panel reactive antibodies (cPRA) ≥99.9% or >98% (with >5 years of waiting time) or, those with cPRA >98% and an human leukocyte antigen (HLA)-incompatible approved living donor who have not received a transplant after 1 year in a paired kidney exchange program. The study will evaluate whether the study treatment is safe and can lower the participant's immune system's sensitization to kidney donors, making it easier to find a well-matched kidney for them. The study treatment is comprised of two drugs, Darzalex® (daratumumab) and Nulojix® (belatacept). Daratumumab is licensed for treatment of multiple myeloma and belatacept is licensed for prevention of rejection after kidney transplant. Eligible participants will receive infusions of daratumumab and belatacept over a 10-week period. An interim safety and efficacy analysis will occur after the first 5 participants have received study treatment. All subjects will undergo HLA antibody assessments and bone marrow aspiration prior to and after completion of treatment and receive 42 weeks of follow up after completing treatment. Participants who prematurely discontinue study therapy will receive follow up through 56 weeks after their baseline visit. Subjects who receive a kidney transplant while in the study will receive standard of care immunosuppression and undergo additional 52 weeks of follow up. Living donors will participate for one study visit to provide blood collection.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Highly Sensitized Prospective Kidney Transplant Recipients
Keywords
calculated panel reactive antibodies (cPRA), desensitization therapy, human leukocyte antigen (HLA) desensitization

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1 (N=5 Subjects)
Arm Type
Experimental
Arm Description
Multiple intravenous infusions of daratumumab and belatacept over 10 weeks: Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit. Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%.
Arm Title
Cohort 2 (N=10 Subjects)
Arm Type
Experimental
Arm Description
The enrollment of ten additional subjects is dependent on the results in Cohort 1. Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:° Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit. Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%. May be modified based on the safety and efficacy analysis of Cohort 1.
Intervention Type
Biological
Intervention Name(s)
daratumumab
Other Intervention Name(s)
Darzalex®, immunoglobulin G1 kappa human monoclonal antibody, IgG1k human mAb
Intervention Description
Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant. Definition of highly sensitized: Potential kidney transplant recipients with either: calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or cPRA >98% (with >5 years of waiting time) awaiting living donor transplant
Intervention Type
Biological
Intervention Name(s)
belatacept
Other Intervention Name(s)
Nulojix®
Intervention Description
Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.
Intervention Type
Procedure
Intervention Name(s)
Bone marrow aspiration
Intervention Description
Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been >4 weeks since the previous bone marrow aspiration.
Primary Outcome Measure Information:
Title
Proportion of subjects who have not met a subject stopping rule and remain free of all of the safety events listed in the outcome description, through 26 weeks after starting treatment or until receiving a transplant, whichever occurs earlier
Description
Proportion of subjects who have not met a subject stopping rule, and remain free of all of the following through 26 weeks after starting treatment or until receiving a transplant, whichever occurs earlier: Grade 3 or higher infusion reaction Grade 3 or higher infections Any malignancy The study site will grade the severity of adverse events experienced by the study subjects according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (Published November 27, 2017).
Time Frame
Baseline up to 26 weeks post treatment initiation
Title
Proportion of subjects who meet any one of the pre-specified events detailed in the outcome description: from Baseline up to Week 26
Description
Proportion of subjects who meet any one of the following compared to Baseline (Visit 0): Elimination of one human leukocyte antigen (HLA) antibody at Visit 12 (16 weeks ±7 days after starting treatment); 50% or greater reduction in the mean fluorescence intensity (MFI) of at least three HLA antibodies at Visit 12 (16 weeks ±7 days after starting treatment); and/or Kidney transplant with a previously incompatible donor within 26 weeks after starting treatment without graft loss due to acute antibody mediated rejection occurring within the first four weeks post-transplant and caused by an anamnestic response.
Time Frame
Baseline (Visit 0) up to 26 weeks post treatment initiation
Secondary Outcome Measure Information:
Title
Proportion of subjects transplanted with a previously incompatible donor within 52 weeks after starting treatment
Description
Subjects may receive a kidney transplant while in the study, either from a living or deceased donor to whom they were previously compatible, or from a previously incompatible donor in case there is a significant reduction in HLA antibody.
Time Frame
Within 52 weeks post treatment initiation
Title
Proportion of subjects with biopsy-proven acute or chronic antibody mediated rejection (AMR) within 52 weeks post-transplant in subjects who undergo a kidney transplant
Description
Antibody mediated rejection (AMR) is an important cause of graft loss after organ transplantation and is caused by anti-donor-specific antibodies, especially anti- human leukocyte antigen (HLA) antibodies.
Time Frame
Within 52 weeks post-transplant
Title
Number of biopsy-proven acute or chronic AMR events within 52 weeks post-transplant in subjects who undergo a kidney transplant
Description
Antibody mediated rejection (AMR) is an important cause of graft loss after organ transplantation and is caused by anti-donor-specific antibodies, especially anti- human leukocyte antigen (HLA) antibodies.
Time Frame
Within 52 weeks post-transplant
Title
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 16 weeks after starting treatment
Description
A measure of infection-related morbidity.
Time Frame
Within 16 weeks post treatment initiation
Title
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 26 weeks after starting treatment
Description
A measure of infection-related morbidity.
Time Frame
Within 26 weeks post treatment initiation
Title
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 52 weeks after starting treatment
Description
A measure of infection-related morbidity.
Time Frame
Within 52 weeks post treatment initiation
Title
Incidence of cytomegalovirus (CMV) disease within 16 weeks after starting treatment
Description
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Time Frame
Within 16 weeks post treatment initiation
Title
Incidence of cytomegalovirus (CMV) disease within 26 weeks after starting treatment
Description
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Time Frame
Within 26 weeks post treatment initiation
Title
Incidence of cytomegalovirus (CMV) disease within 52 weeks after starting treatment
Description
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Time Frame
Within 52 weeks post treatment initiation
Title
Incidence of cytomegalovirus (CMV) infection within 52 weeks after starting treatment
Description
CMV infection confirmed by the presence of detectable CMV in blood by polymerase chain reaction [PCR] diagnostic testing, regardless of whether signs or symptoms are present.
Time Frame
Within 52 weeks post treatment initiation
Title
Incidence of post-transplant lymphoproliferative disorder (PTLD)
Description
As per diagnosis by local pathologist and treating physician.
Time Frame
Within 52 weeks post-transplant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Individuals who meet all of the following criteria are eligible for enrollment as study subjects- Subject must be able to understand and provide informed consent End stage renal disease (ESRD) on hemodialysis United Network for Organ Sharing (UNOS) listed listed with current calculated panel reactive antibodies (cPRA) ≥99.9% or >98% (with >5 years of waiting time) awaiting deceased donor transplant --Note: Those with cPRA >98% with human leukocyte antigen (HLA)-incompatible approved living donor who have not received a transplant after 1 year in a paired kidney exchange program are also eligible Evidence of established immunity to Epstein-Barr Virus (EBV) as demonstrated by serologic testing Negative result of most recent tuberculosis (TB) testing or appropriately completed latent TB infection (LTBI) therapy. Testing should be conducted using either a PPD or interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB) Results from tests performed within 12 months prior to study entry are acceptable in the absence of any intervening exposure to TB Subjects with a positive test for LTBI must complete appropriate therapy for LTBI ---LTBI treatment regimens should be among those endorsed by the Centers for Disease Control and Prevention (CDC), Division of TB Elimination, url: https://www.cdc.gov/tb/topic/treatment/ltbi.htm Negative Food and Drug Administration (FDA)-approved test for human immunodeficiency virus (HIV) diagnosis (at screening or as documented in medical record, up to 12 months prior to screening) Negative Hepatitis C antibody test at screening or as documented in medical record, up to 12 months prior to screening --If there is a history of treated hepatitis C or there is a suspected false positive hepatitis C virus (HCV) antibody test, then documentation of two consecutive negative HCV quantitative ribonucleic acid (RNA) Polymerase chain reaction (PCR) tests separated by at least 6 months is required Negative result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase (RT-PCR) Female subjects of reproductive potential must have a negative pregnancy test upon study entry All subjects of reproductive potential must agree to use of contraception for the duration of the study Subjects must have current vaccinations or documented immunity to varicella, measles, hepatitis B, pneumococcus, influenza, and zoster (if ≥50 years old) If subjects require administration of vaccines to meet eligibility requirements, they must wait at least 2 weeks between vaccination and the baseline (Visit 0) visit Exclusion Criteria: Individuals who meet any of these criteria are not eligible for enrollment as study subjects- Inability or unwillingness of a subject to give written informed consent or comply with study protocol Known active current or history of invasive fungal infection or non-tuberculous mycobacterial infection Hepatitis B surface antigen or core antibody positive Serious uncontrolled concomitant major organ disease excluding kidney failure Previous non-kidney solid organ or bone marrow transplant Any infection requiring hospitalization and intravenous (IV) antibiotics within 4 weeks of screening or by mouth (PO) antibiotics within 2 weeks Primary or secondary immunodeficiency History of active tuberculosis (TB), even if treated History of positive result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase (RT-PCR) Malignancy within the last 5 years except treated basal and squamous cell cancer of the skin or treated in situ cervical cancer History of plasma cell dyscrasia Alcohol, drug, or chemical abuse within 1 year Difficult peripheral venous access Need for uninterrupted anticoagulation Neutropenia (absolute neutrophil count <1000/uL) or thrombocytopenia (platelet count <100,000/uL) within 4 weeks prior to study enrollment Women who are currently pregnant or nursing Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational drug, whichever is longer) of screening Current treatment with other biological drug Immunization with live vaccine within 2 weeks of study baseline (Visit 0) visit Past or current medical problems or findings from physical examination or laboratory testing not listed above, which, in the opinion of the investigator, may: pose additional risks from participation in the study, interfere with the subject's ability to comply with study requirements, or impact the quality or interpretation of the data obtained from the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Flavio G. Vincenti
Organizational Affiliation
UCSF Kidney Transplant Research
Official's Role
Study Chair
Facility Information:
Facility Name
University of California at San Francisco Medical Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shreya Mall
Phone
415-353-8380
Email
shreya.mall@ucsf.edu

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD Sharing Time Frame
On average, within 24 months after database lock for the trial.
IPD Sharing Access Criteria
Open access.
IPD Sharing URL
https://www.immport.org/home
Links:
URL
https://www.niaid.nih.gov/about/dait
Description
Division of Allergy, Immunology, and Transplantation (DAIT)
URL
https://www.niaid.nih.gov/
Description
National Institute of Allergy and Infectious Diseases (NIAID)
URL
https://www.immunetolerance.org/
Description
Immune Tolerance Network (ITN)

Learn more about this trial

Daratumumab and Belatacept for Desensitization

We'll reach out to this number within 24 hrs